Healthcare
FNArena Windows (Sectors)
Introduction to FNArena Windows
FNArena Windows offers subscribers the option to investigate ASX-listed stocks against their peers. FNArena developed its own sector methodology which in our view overcomes many flaws and disadvantages connected with GICS sectors. Our system starts with three broad sector labels: COMMODITIES, FINANCIAL SERVICES and INDUSTRIALS. From here onwards subscribers can explore further through gradually narrowing branches. This is not investment advice, but simply another window on the Australian Stock Exchange to provide better insight and to assist FNArena subscribers while conducting their own market analysis.
Latest Stories
The New Criterion’s Tim Boreham uncovers the potential of 4D Medical in the USA
Apr 23 2024
Race Oncology tells a story all too familiar among developing Aussie biotechs, Tim Boreham reports
Apr 09 2024
| ASX CODE | COMPANY NAME | LAST PRICE | 52WK HIGH | 52WK LOW | P/E | CONSENSUS TARGET |
|---|---|---|---|---|---|---|
| 4DX | 4DMEDICAL LIMITED | $0.61 | $1.27 | $0.45 |
$1.15 |
|
| ACL | AUSTRALIAN CLINICAL LABS LIMITED | $2.41 | $3.69 | $2.26 | 15.6 |
$3.133 |
| ALC | ALCIDION GROUP LIMITED | $0.05 | $0.13 | $0.04 |
$0.05 |
|
| APM | APM HUMAN SERVICES INTERNATIONAL LIMITED | $1.18 | $2.25 | $0.68 | 12.7 |
$1.60 |
| ARX | AROA BIOSURGERY LIMITED | $0.50 | $1.09 | $0.48 |
$1.05 |
|
| AVH | AVITA MEDICAL INC | $2.78 | $xx.xx | $xx.xx | xx.x | xx.xx |
| BMT | BEAMTREE HOLDINGS LIMITED | $0.18 | $xx.xx | $xx.xx | xx.x | xx.xx |
| CAJ | CAPITOL HEALTH LIMITED | $0.22 | $xx.xx | $xx.xx | xx.x | xx.xx |
| CAT | CATAPULT GROUP INTERNATIONAL LIMITED | $1.41 | $xx.xx | $xx.xx | xx.x | xx.xx |
| COH | COCHLEAR LIMITED | $323.05 | $xx.xx | $xx.xx | xx.x | xx.xx |
| CSL | CSL LIMITED | $275.47 | $xx.xx | $xx.xx | xx.x | xx.xx |
| CU6 | CSL LIMITED | $2.60 | $xx.xx | $xx.xx | xx.x | xx.xx |
| CUV | CLINUVEL PHARMACEUTICALS LIMITED | $14.25 | $xx.xx | $xx.xx | xx.x | xx.xx |
| CYC | CYCLOPHARM LIMITED | $1.78 | $xx.xx | $xx.xx | xx.x | xx.xx |
| DOC | DOCTOR CARE ANYWHERE GROUP PLC | $0.06 | $xx.xx | $xx.xx | xx.x | xx.xx |
| EBO | EBOS GROUP LIMITED | $32.12 | $xx.xx | $xx.xx | xx.x | xx.xx |
| EBR | EBR SYSTEMS INC | $0.86 | $xx.xx | $xx.xx | xx.x | xx.xx |
| FPH | FISHER & PAYKEL HEALTHCARE CORPORATION LIMITED | $24.09 | $xx.xx | $xx.xx | xx.x | xx.xx |
| GSS | GENETIC SIGNATURES LIMITED | $0.68 | $xx.xx | $xx.xx | xx.x | xx.xx |
| HLS | HEALIUS LIMITED | $1.25 | $xx.xx | $xx.xx | xx.x | xx.xx |
| IDX | INTEGRAL DIAGNOSTICS LIMITED | $2.54 | $xx.xx | $xx.xx | xx.x | xx.xx |
| IME | IMEXHS LIMITED | $0.54 | $xx.xx | $xx.xx | xx.x | xx.xx |
| IMM | IMMUTEP LIMITED | $0.36 | $xx.xx | $xx.xx | xx.x | xx.xx |
| IMR | IMRICOR MEDICAL SYSTEMS INC | $0.52 | $xx.xx | $xx.xx | xx.x | xx.xx |
| IMU | IMRICOR MEDICAL SYSTEMS INC | $0.09 | $xx.xx | $xx.xx | xx.x | xx.xx |
| INA | INGENIA COMMUNITIES GROUP | $4.81 | $xx.xx | $xx.xx | xx.x | xx.xx |
| IPD | IMPEDIMED LIMITED | $0.09 | $xx.xx | $xx.xx | xx.x | xx.xx |
| LIC | LIFESTYLE COMMUNITIES LIMITED | $14.25 | $xx.xx | $xx.xx | xx.x | xx.xx |
| M7T | MACH7 TECHNOLOGIES LIMITED | $0.68 | $xx.xx | $xx.xx | xx.x | xx.xx |
| MAP | MICROBA LIFE SCIENCES LIMITED | $0.17 | $xx.xx | $xx.xx | xx.x | xx.xx |
| MDR | MEDADVISOR LIMITED | $0.27 | $xx.xx | $xx.xx | xx.x | xx.xx |
| MPL | MEDIBANK PRIVATE LIMITED | $3.64 | $xx.xx | $xx.xx | xx.x | xx.xx |
| MSB | MESOBLAST LIMITED | $0.80 | $xx.xx | $xx.xx | xx.x | xx.xx |
| MVF | MONASH IVF GROUP LIMITED | $1.49 | $xx.xx | $xx.xx | xx.x | xx.xx |
| MX1 | MICRO-X LIMITED | $0.09 | $xx.xx | $xx.xx | xx.x | xx.xx |
| NAN | NANOSONICS LIMITED | $2.81 | $xx.xx | $xx.xx | xx.x | xx.xx |
| NEU | NEUREN PHARMACEUTICALS LIMITED | $19.28 | $xx.xx | $xx.xx | xx.x | xx.xx |
| NHF | NIB HOLDINGS LIMITED | $7.55 | $xx.xx | $xx.xx | xx.x | xx.xx |
| PAR | PARADIGM BIOPHARMACEUTICALS LIMITED | $0.29 | $xx.xx | $xx.xx | xx.x | xx.xx |
| PBP | PROBIOTEC LIMITED | $2.86 | $xx.xx | $xx.xx | xx.x | xx.xx |
| PER | PERCHERON THERAPEUTICS LIMITED | $0.08 | $xx.xx | $xx.xx | xx.x | xx.xx |
| PGC | PARAGON CARE LIMITED | $0.34 | $xx.xx | $xx.xx | xx.x | xx.xx |
| PME | PRO MEDICUS LIMITED | $104.10 | $xx.xx | $xx.xx | xx.x | xx.xx |
| PNV | POLYNOVO LIMITED | $1.98 | $xx.xx | $xx.xx | xx.x | xx.xx |
| PSQ | PACIFIC SMILES GROUP LIMITED | $1.67 | $xx.xx | $xx.xx | xx.x | xx.xx |
| REG | REGIS HEALTHCARE LIMITED | $3.90 | $xx.xx | $xx.xx | xx.x | xx.xx |
| RHC | RAMSAY HEALTH CARE LIMITED | $51.08 | $xx.xx | $xx.xx | xx.x | xx.xx |
| RMD | RESMED INC | $28.19 | $xx.xx | $xx.xx | xx.x | xx.xx |
| SHL | SONIC HEALTHCARE LIMITED | $26.45 | $xx.xx | $xx.xx | xx.x | xx.xx |
| TLX | TELIX PHARMACEUTICALS LIMITED | $14.10 | $xx.xx | $xx.xx | xx.x | xx.xx |
| TRJ | TRAJAN GROUP HOLDINGS LIMITED | $1.13 | $xx.xx | $xx.xx | xx.x | xx.xx |
| VHT | VOLPARA HEALTH TECHNOLOGIES LIMITED | $1.14 | $xx.xx | $xx.xx | xx.x | xx.xx |
Previous Stories
The Power Of New Weight-Loss Drugs
Apr 03 2024
GLP-1s offer far more across the healthcare sector than just weight-loss, with far-reaching societal implications, explains T. Rowe Price’s Nabil Hanano
Dr Boreham’s Crucible: Hydrix
Mar 26 2024
Tim Boreham highlights Hydrix as one of the most innovative small-cap healthcare companies on the ASX
Treasure Chest: Lifestyle Communities En Vogue
Mar 19 2024
FNArena’s Treasure Chest reports on money making ideas from stockbrokers and other experts. Today’s idea is on Lifestyle Communities
Uptrend Resumed For ResMed
Mar 19 2024
Shares in ResMed seem positioned for a new 2024 high, reports Michael Gable of Fairmont Equities
Capitol Health’s Higher Margin Outlook
Mar 13 2024
Capitol Health’s first half results exceeded brokers’ expectations with higher margins thanks largely to stringent cost control
Rudi’s View: Healthcare Under The Scanner
Mar 13 2024
In this week's Weekly Insights: -Healthcare Under The Scanner-February 2024; The Final Verdict-Rudi Unplugged, In April By Rudi Filapek-Vandyck, Editor…
Dr Boreham’s Crucible: Neuren Pharmaceuticals
Mar 11 2024
Tim Boreham reports Neuren Pharmaceuticals has suffered from accusations from an activist shorter which others have debunked
Dr Boreham’s Crucible: Cochlear
Feb 28 2024
The New Criterion’s Tim Boreham explains the business case for Cochlear
Rudi Interviewed: Ongoing Potential In Technology & Growth
Feb 19 2024
It has become the 'unofficial' tradition in recent years: an interview with Livewire Markets ahead of yet another corporate reporting…
Dr Boreham’s Crucible: Artrya
Feb 15 2024
Artificial intelligence and some valuable experiences should benefit heart device developer Artrya, Tim Boreham explains
Latest News
| 1 |
ASX Winners And Losers Of Today – 23-04-24Apr 23 2024 - Daily Market Reports |
| 2 |
Australian Broker Call *Extra* Edition – Apr 23, 2024Apr 23 2024 - Daily Market Reports |
| 3 |
Uranium Week: From Russia Without LoveApr 23 2024 - Weekly Reports |
| 4 |
Weekly Update On LICs & LITs – 23-Apr-2024Apr 23 2024 - Weekly Reports |
| 5 |
Dr Boreham’s Crucible: 4D MedicalApr 23 2024 - Small Caps |